Global Ophthalmic Eye Drops Industry Anticipating a 4.2% CAGR Boost to Reach US$24.53 Billion by 2033 | FMI Inc.

The Global Ophthalmic Eye Drops Industry stands as a luminous beacon in the expansive healthcare landscape, illuminating a path of unprecedented growth. According to the latest insights from Future Market Insights (FMI), the industry is primed to achieve a remarkable valuation of US$ 16.21 billion in 2023, propelled by its immense potential and significant market dynamics.

FMI's visionary perspective paints a compelling picture of the industry's future, foreseeing a soaring ascent beyond current heights. The Global Ophthalmic Eye Drops Industry is anticipated to exceed a valuation of US$ 24.53 billion by 2033, underpinned by a robust Compound Annual Growth Rate (CAGR) of 4.2%. This projection showcases a vivid tapestry of success and underscores the industry's resilience and potential for sustained growth.

The driving force behind this remarkable trajectory is the escalating cases of eye infections, acting as a catalyst for the surge in ophthalmic eye drop sales. The industry's positive outlook for growth is underscored by FMI's comprehensive analysis, highlighting the pivotal role played by these medicinal solutions in addressing prevalent eye health concerns.

Request a Sample of this Report Now!
https://www.futuremarketinsights.com/reports/sample/rep-gb-13140

New eye drop product launches, branded as well as generic, are expected to be hampered in the short term due to disruptions in the supply chain, delayed pipeline research and development, and a shift in the priority of leading healthcare companies to COVID-19 vaccine and treatment developments.

According to the report, institutional sales of ophthalmic eye drops will rise considerably in the coming years. It will account for over half of ophthalmic eye drops sold through the forecast period.

“Increasing prevalence of eye infections, technological advancements, and high risk of infections from the increasing use of contact lens is expected to boost the growth of the Global Ophthalmic Eye Drops Industry.” says Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.).

Key Takeaways from Global Ophthalmic Eye Drops Industry Study

• Ophthalmic eye drops market will expand consistently to surpass a valuation of US$ 15 Bn by 2021
• The U.S. holds over 92.1% share of the North American market, but Canada is projected to expand faster at around 4.0% CAGR
• Rising cases of eye infection will drive sales in the U.K., enabling it to register 3.9% y-o-y growth in 2021
• Rising willingness to spend on advanced eye care will drive sales in Germany and France
• Expansion of the healthcare sector will emerge as the chief growth driver in China and Japan. Both countries will exhibit a high demand for dilation drops

Due to their increasingly active lifestyle and desire for better aesthetics, many people are shifting to contact lenses. However, many ocular infections are associated with the use of contact lenses. Each year in the United States, approximately 1 million eye infections occur related primarily to keratitis, a fungal infection of the cornea, and contact lens infections account for estimated direct costs of $175 million. In addition, 40.9 million U.S. adults wear contact lenses, and 99% of 4,269 contact lens wearers reported at least one contact lens–related hygiene behavior associated with an increased risk for eye infection or inflammation. Nearly a million eye infections requiring a trip to the doctor happen each year, many of them related to contact lens use.

Reach Out to Our Analyst For Your Queries
https://www.futuremarketinsights.com/ask-question/rep-gb-13140

Who is Winning?

The top players are focusing on increasing acquisitions at the regional level. Acquisitions empower the company with products and increase the company’s portfolio. The company acquires other players to possess well-established products and solutions that are expected to become a good revenue source for the acquirer. Acquisitions also enable the company to enter new emerging markets as well as enhance its presence in existing markets. Furthermore, key market players such as Novartis and Gerresheimer AG are focusing on the expansion of their market reach in different regions. For example-

• In November 2020, Gerresheimer Regensburg announced that it was expanding its production area in Germany. The company has planned the expansion of its production capacity in small batch production, as a result of increasing development projects for pharmaceutical and medical technology products.
• In November 2019, Sandoz announced that it has entered into a binding agreement for the planned acquisition of the Japanese business of Aspen Global Incorporated (AGI), a wholly owned subsidiary of Aspen Pharmacare Holdings Limited, strengthening its position in the world’s third-largest generics market.

Some of the key market players covered by FMI include Novartis AG, Bausch & Lomb, Akorn, Inc., Biomedica, AdvaCare Pharma, C2 PHARMA, Kraeber GmbH, Iskon Remedies, HANSHIN GROUP, Berry Global Inc., Nolato AB, Bormioli Pharma, WG Pro-Manufacturing Inc., Gerresheimer AG, Adelphi Healthcare Packaging, Aptar Group Inc., and Amcor Plc.

Click Here To Buy Your Full Report
https://www.futuremarketinsights.com/checkout/13140

Global Ophthalmic Eye Drops Industry by CategoryDrug Class

• Anesthetic Drops
• Dilation Drops
• Glaucoma Drops
• Steroid Drops
• Antibiotic Drops
• Others (Antihistamines, Lubricants Tear Drops)

Indication

• Dry Eye
• Eye Allergy
• Glaucoma
• Eye Infection
• Retinal Disorders
  • Macular Degeneration
  • Diabetic Retinopathy
  • Others
• Uveitis
• Others

Drug Formulation

• With Preservative
• Preservative Free

Container Type

• Single Dose Container
• Multiple-Dose Container

Distribution Channel

• Institutional Sales
  • Hospitals
  • Community Clinics
  • Ophthalmic Clinics
  •  Public Health Agencies
  • Veterinary Hospitals & Clinics
• Retail Sales
  • Retail Pharmacies
  •  Drug Stores

Author

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.